KAPA — Kairos Pharma, Ltd.
Is KAPA overbought or oversold? Here is the current MarketMoodz read.
Kairos Pharma, Ltd. (KAPA) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $0.41. The rating moved from Strong Oversold to Oversold on November 17, 2026.
- Public ratingOversold (as of November 17, 2026)
- Last close$0.41
- Last changeMoved from Strong Oversold to Oversold on November 17, 2026
- SectorHealthcare
- IndustryBiotechnology
See all oversold Healthcare stocks →
AI analysis
Kairos Pharma, Ltd. (KAPA) appears to be a small, early-stage biotech with limited public financial disclosure and exposure to binary clinical and financing outcomes. Financial health is uncertain due to absent recent filings and likely cash-burn dynamics; this elevates dilution risk and short-term vulnerability. Market positioning offers upside only if a program achieves positive clinical or partnering milestones, but the competitive landscape and sector flows favor larger, defensive pharma names, making investor appetite for micro-cap biotech limited. Social sentiment and recent-development visibility are minimal, reducing near-term positive momentum. Most probable scenarios include downside pressure from funding needs or negative trial news; a narrower upside scenario requires successful readouts or partnership/licensing deals that could materially reprice the equity.
Key factors
- Limited public financial disclosure and no recent EDGAR comparables available, increasing uncertainty about cash runway and burn
- Early-stage / small-cap biotech profile: value is highly dependent on binary clinical/regulatory milestones and potential partnering or M&A
- Low share price and likely low liquidity, which amplifies volatility and downside in negative news or funding events
- Sector backdrop favoring large-cap pharma and defensive healthcare flows, which can reduce investor appetite for micro‑cap biotech risk
- Convertible-debt and broader biotech dilution pressures in the sector increase probability of future equity issuance
- Potential upside catalysts exist (trial readouts, partnerships, licensing) but are binary and timing is uncertain
Risks
- Binary clinical or regulatory failure that could materially impair valuation
- Insufficient cash runway leading to dilutive financing at unfavorable terms
- Severe share illiquidity and high volatility; risk of rapid, large downmoves or inability to enter/exit positions
- Competition from larger, better-capitalized pharma/biotech players with overlapping programs or superior commercial capabilities
- Adverse sector rotation away from small-cap biotech or broader market risk-off that reduces financing access
- Operational execution risks (manufacturing, trial enrollment, data integrity) given small organization scale
- Reimbursement and commercialization risk if a product candidate reaches late-stage success
See today's live rating, score and targets
Members see the live hourly rating for KAPA — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.